Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France (CORSER)
Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples
Sponsor: Institut Pasteur
This observational or N/A phase trial investigates COVID-19 and SARS (Severe Acute Respiratory Syndrome) and is currently completed. Institut Pasteur leads this study, which shows 14 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Aug 2023 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Apr 2022 — Aug 2023 [monthly]
Recruiting
▶ Show 9 earlier versions
-
Dec 2021 — Apr 2022 [monthly]
Recruiting
-
Sep 2021 — Dec 2021 [monthly]
Recruiting
-
Feb 2021 — Sep 2021 [monthly]
Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Recruiting
-
Jul 2020 — Oct 2020 [monthly]
Recruiting
-
May 2020 — Jul 2020 [monthly]
Recruiting
-
Apr 2020 — May 2020 [monthly]
Recruiting
First recorded
Mar 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut Pasteur
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Asnières-sur-Seine, France , Dijon, France , La Roche-sur-Yon, France , Limoges, France , Lyon, France , Mennecy, France , Nancy, France , Orléans, France , Paris, France and 6 more locations